SEC Tracker
Get the app

ReShape Lifesciences HIND

ReShape Lifesciences FY 2023: revenue $8.7M, down 23%; diluted EPS −$163,303.69

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.6
Material contract

Key figures from this report

These are the numbers ReShape Lifesciences reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$8.7M−23% from $11.2M in FY 202210-K income statement, on EDGAR
  2. Net income−$11.4MAgainst −$46.2M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$163,303.69Against −$9,310,875.51 in FY 2022. Split-adjusted, as the tables show it; the filing reported −$1.9110-K income statement, on EDGAR
  4. Cash and cash equivalents$4.5M+16% from $3.9M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$17.0MAgainst −$21.9M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when ReShape Lifesciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025
  4. Natural Alternatives International NAII public float $6M, Dec 31, 2025
  5. LFTD Partners LIFD public float $6M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.